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Abstract 
The significant morbidity that accompanies stroke makes it one of the world’s most 
devastating neurological disorders. Currently, proven effective therapies have been 
limited to thrombolysis and thrombectomy. The window for the administration of these 
therapies is narrow, hampered by the necessity of rapidly imaging patients. A therapy 
that could extend this window by protecting neurons may improve outcome. 
Endogenous neuroprotection has been shown to be, in part, due to changes in mTOR 
signalling pathways and the instigation of productive autophagy. Inducing this effect 
pharmacologically could improve clinical outcomes. One such therapy already in use in 
transplant medicine is the mTOR inhibitor rapamycin. Recent evidence suggests that 
rapamycin is neuroprotective, not only via neuronal autophagy but also through its 
broader effects on other cells of the neurovascular unit. This review highlights the 
potential use of rapamycin as a multimodal therapy, acting on the blood brain barrier, 
cerebral blood flow and inflammation, as well as directly on neurons. There is 
significant potential in applying this old drug in new ways to improve functional 
outcomes for patients after stroke.  
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Introduction 
An increasing prevalence of vascular risk factors in low- and middle-income countries 
is expected to result in 12 million stroke-related deaths annually by 2030, amounting to 
a global loss of over 200 million disability-adjusted life years (DALYs).1 Whilst our 
understanding of pathophysiology of stroke has grown exponentially during the last few 
decades, the only available acute therapies target reperfusion of the ischemic tissue2 –
there are currently no clinically proven neuroprotectants that can delay cell death and 
extend the therapeutic time window to restore blood flow.3 In ischemic stroke, the 
occlusion of blood vessels in the brain heralds the beginning of a neurotoxic cascade. 
Tissue immediately adjacent to the core of the infarct (known as penumbra) has residual 
cerebral blood flow, is electrically silent due to impaired cellular energy availability, but 
is not yet irreversibly damaged and therefore may be salvageable if reperfusion occurs.4 
Any intervention once the cascade has been triggered at best amounts to damage 
limitation. Translating promising findings from in vitro studies and animal models has 
proven incredibly challenging.5 The complexity of the processes implicated in ischemic 
cell death diminish the likelihood of achieving benefit from targeting these mechanisms 
with monotherapies. Our focus should be on multifactorial approaches, countering the 
multiple pathological processes and ensuring we target the earliest steps in the cascade 
of pathogenesis.  
Despite the neurotoxic cascade occurring during a stroke, some neurons have an innate 
ability to survive brief episodes of ischemia. In cardiac arrest, or the rodent model of 
global transient ischemia, the CA3 neurons of the hippocampus are resistant whereas 
the CA1 neurons are vulnerable to the ischemic insult.6-13 Pharmacologically 
manipulating this inherent capacity to withstand the effects of a stroke may be key to 
the development of novel therapies. Hamartin expression has been shown to be partly 
responsible for this endogenous neuroprotection.14 Hamartin is the protein product of 
the gene Tsc1. Together with tuberin (Tsc2), it forms the tuberous sclerosis complex 
(TSC), which inhibits the mammalian target of rapamycin complex 1 (mTORC1) and 
acts as a tumour suppressor.15 Pharmacologically, mTORC1 can be inhibited by 
rapamycin (sirolimus), a macrolide compound widely used as an immunosuppressant. 
The mTORC1 pathway is remarkably well conserved phylogenetically and expressed in 
all human cell types, reflecting its role as a central regulator of metabolism (Human 
Protein Atlas, www.proteinatlas.org).16 Whilst harnessing this pathway could prove 
useful, we first need to understand the potential multifaceted effects that rapamycin and 
mTOR inhibition may have, both centrally and peripherally, following stroke. 
Historically, there has been contradictory evidence in the literature surrounding animal 
models of ischemic stroke as to whether rapamycin is neuroprotective or detrimental to 
outcomes. A systematic review of these studies has found significant evidence that 
rapamycin improves not only infarct volume but also behavioral outcomes after 
experimental stroke and that this may be dose-dependent (Beard et al., under review). 
The inhibition of mTOR by rapamycin results in a plethora of downstream effects 
including productive autophagy, alteration of cerebral blood flow, reduction in blood-
brain barrier (BBB) permeability and cytoskeletal changes. Instead of taking the 
traditional view that the multitude of off-target effects of rapamycin preclude its 
consideration clinically in acute central nervous system (CNS) injury, we take the view 
that a multimodal approach is exactly what is required to improve outcome following 
ischemic stroke.   
Molecular mechanisms of rapamycin 
There are two mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2), differing in their subunit composition. The regulatory associated protein of 
mTOR (raptor) is found in mTORC1, whereas the rapamycin-insensitive companion of 
mTOR (rictor) is in mTORC2.17 The main function of mTORC1 is to augment protein 
synthesis and inhibit autophagy (Figure 1A).  Both mTORC1 and mTORC2 have been 
postulated to play roles in cell survival, cell proliferation and regulating the 
cytoskeleton.18, 19 Activators of mTORC2 activity include growth factors and insulin 
through the PI3K pathway.20, 21 Many of the upstream regulatory pathways converge at 
the tuberous sclerosis complex (TSC), allowing it to play an important role in the 
control of mTOR activity. The overall effect of impaired TSC activity is mTOR 
hyperactivation, which results in uncontrolled protein synthesis and inhibition of 
autophagy.15 
As the name suggests, the major small molecule inhibitor of mTOR is rapamycin. 
However, the plethora of diseases in which mTOR dysregulation has been implicated 
has paved the way for the development of novel drugs targeting this pathway. First 
generation mTOR inhibitors, or rapalogs, aim to directly inhibit the mTOR complex by 
preventing the binding of raptor and thus the activation of mTOR, rendering it incapable 
of phosphorylating downstream molecules. These first generation inhibitors include 
drugs such as sirolimus and temsirolimus.22  
Second generation, more selective, mTOR inhibitors also decrease cell cycle 
progression and protein production, but selective targeting can push them via either the 
AKT or the S6K pathways and, in theory, affect either cell death and the induction of 
autophagy (mTORC1) or cell survival and function (mTORC2).23 However, since the 
first generation inhibitors have been used in the majority of preclinical studies and 
importantly have extensive clinical safety data, this review will focus on the application 
of these compounds to cerebral ischemia.  
Promoting neuronal survival in ischemic conditions 
The efficient disposal of superfluous and detrimental proteins is essential for tissues 
with limited regenerative capacity, such as the CNS.24 A key mechanism through which 
this is achieved is autophagy, the engulfment of misfolded, damaged or surplus proteins 
and organelles in a lipid bilayer, which are subsequently targeted for degradation 
(Figure 1B).25, 26 Dysfunction of basal autophagy has been shown to rapidly lead to 
formation of protein inclusions and neurodegeneration in rodent models.27 The 
relevance of autophagy to stroke is its role as an adaptive response to provide nutrients 
and energy from pre-existing sources, during episodes of cellular stress when there is 
limited nutrient delivery through the vasculature. 
Current hypotheses suggest that a short, sharp period of “austerity” might induce 
cellular tolerance to ischemia.14, 28 The up-regulation of hamartin-induced mTOR 
inhibition with ischemic preconditioning could provide the underlying mechanism for 
this tolerance14, and is entirely consistent with the idea that hypothermia29 and 
deafferentation,30 might result in increased survival of brain cells following ischemia. 
Preconditioning with rapamycin (administered 20 hours before ischemia) has been 
shown to induce autophagy, improve survival, longevity, infarct size and behavioural 
scores following focal cerebral ischemia/reperfusion.31 Similarly, in a model of 
permanent focal ischemia, ischemic preconditioning (IPC) reduced infarct volume, 
brain edema and motor deficit.32 These protective effects were abolished when 
autophagy was inhibited by 3-methyladenine (3-MA). Furthermore, rapamycin 
treatment on its own mimicked the protective effects of IPC. Together these data show 
that the mechanisms of neuroprotection by both rapamycin and pre-conditioning appear 
to both be mediated through the induction of autophagy.  
In certain experimental systems, suppressing autophagy in response to oxidative, 
hypoxic-ischemic, and excitotoxic injuries confers neuroprotection, linking the over-
activation of autophagy to neuronal injury.24 The suppression of autophagy by exercise 
pre-treatment and MAPK (p38) inhibition was demonstrated to be neuroprotective in a 
middle cerebral artery occlusion (MCAO) model of stroke.33 A number of other studies 
show that autophagy has a detrimental effect in the context of neuronal ischemia.34-38 In 
an attempt to reconcile conflicting findings, one study has compared an inducer of 
autophagy (rapamycin) with an inhibitor (chloroquine).39 Both compounds reduced 
infarct size and ameliorated neurological scores, but only the rapamycin-treated mice 
demonstrated improved survival.39, 40 Interestingly, the neuroprotective effects of 
rapamycin were reversed by the autophagy inhibitor 3-MA.41 In IPC32, 42 and remote 
ischemic post-conditioning,43 autophagy was demonstrated to be neuroprotective. 
However, autophagy inhibition also was found to be neuroprotective in ischemic post-
conditioning.44 In isolated neuronal cultures, excitotoxic glutamate insults were shown 
to block autophagic flux, and inhibition of autophagy had no effect on neuronal 
survival.45 In contrast, the same study found significant neuroprotection with rapamycin 
and trehalose, two inducers of autophagy that work via mTOR-dependent and mTOR-
independent mechanisms, respectively.45 These studies clearly demonstrate that 
autophagy has both protective and detrimental effects on neurons, which can be 
influenced by the administration of rapamycin (Figure 1C). 
In an attempt to address the apparent equipoise in the literature and explain the 
heterogeneous outcomes produced by rapamycin, a systematic review and meta-analysis 
conducted on rodent models of focal ischemia has demonstrated that in vivo rapamycin 
is neuroprotective with a reduction in infarct volume and improvement in behavioural 
outcomes. (Beard et al., under review) The neuroprotective effects of rapamycin were 
dose-dependent with lower doses associated with improved outcomes, potentially by 
inducing an optimal level of autophagy to enable viable neurons to survive in an austere 
environment, without causing excessive neuronal death.  
Beyond the neuron: The neurovascular unit 
Stroke research is increasingly focussing on the neurovascular unit (NVU). Neurons in 
vivo do not act in isolation, therefore their interactions with the vasculature and 
surrounding glia, and the implications these have for neuroprotective therapies, must be 
considered (Figure 2).46, 47 The NVU plays an important role in maintaining a constant 
cerebral microenvironment, regulating cerebral blood flow (CBF), inducing and 
subsequently maintaining the BBB.48 Stroke has been shown to cause to damage to, and 
subsequent dysfunction of, the NVU.49-53  
Timely reperfusion is a crucial goal for acute stroke therapies. However, it may also 
contribute to secondary neuronal damage, hemorrhagic transformation and cytotoxic 
edema formation. BBB permeability/vasogenic edema is one of the leading causes of 
patient deterioration following stroke.54 Early animal studies revealed a triphasic 
increase in BBB permeability following reperfusion,55, 56 with an initial peak upon 
reperfusion, followed by a limited amount of recovery of BBB integrity with evidence 
of multifocal BBB permeability to albumin, possibly by enhanced transcytosis as early 
as two hours of reperfusion.57 This is followed by later peaks in permeability at 6 and 72 
hours after stroke, most likely due to loss of tight junctions leading to vasogenic 
edema.58-62 Furthermore, vessel recanalization does not always result in microvascular 
reperfusion, ultimately limiting the effectiveness of thrombolytic treatments.63-73 It is 
estimated that around twenty-five percent of stroke patients that achieve successful 
recanalization do not achieve reperfusion (termed futile reperfusion or the no-reflow 
phenomenon).74 The mechanisms of this phenomenon are difficult to study in humans. 
No-reflow and post-reperfusion hypoperfusion are well-established concepts in 
experimental ischemia, where opening of the occluded vessel fails to return adequate 
capillary perfusion.75, 76 Evidence from animal studies suggest a number of mechanisms 
for this phenomenon including astrocyte end-feet swelling,77 neutrophil entrapment,78 
and pericyte death in rigour.79, 80  
Previously in the setting of ischemia, rapamycin has been used to investigate the role of 
neuronal autophagy. However, we are only just beginning to explore the potential for 
rapamycin to have an effect on the rest of the NVU. In the following section, the effect 
of rapamycin on BBB integrity will be discussed, as well the potential for rapamycin to 
ameliorate other aspects of neurovascular dysfunction after stroke.  
Improving CBF  
Rapamycin treatment can alter blood flow in neurological disease. mTORC1 inhibition 
was shown to improve basal CBF, BBB integrity and was associated with amelioration 
of behavioural outcomes in models of Alzheimer’s disease.81 The restoration of brain 
vascular integrity and function in the hAPP (J20) mouse model of Alzheimer’s disease 
is attributable to endothelial NO synthase activation through rapamycin’s inhibition of 
mTOR leading to increased activity of eNOS (Figure 2).82 In a study using a murine 
low-density lipoprotein receptor model of atherosclerosis and vascular cognitive 
impairment, rapamycin restored CBF and brain vascular density.83  
Only one in vivo stroke study has measured CBF following rapamycin treatment.84 
Although this study reported a non-significant increase in CBF at 2 hours post-
reperfusion, there was an increase in infarct volume measured at the same time. This 
discrepancy may be explained by the chronic (3 days) high-dose infusion (20 mg/kg) of 
rapamycin used in this study. This regimen resulted in inhibition of mTORC2, which is 
required for adaptation and survival during cellular stress.19 The authors highlight that 
optimising their dosage and timing of administration is needed to ensure inhibition of 
predominantly mTORC1 to obtain the beneficial effects of rapamycin treatment. The 
results of the meta-analysis of Beard et al. (under review) suggest that lower doses of 
rapamycin (<1mg/kg) are associated with improved outcome. 
mTOR inhibition with rapamycin may improve neurovascular function by autophagy-
dependent and autophagy-independent mechanisms. For example, the mTOR pathway 
may be implicated in autoregulatory failure following reperfusion. Autoregulatory 
failure begins as early as 30 minutes after experimental MCAO in rodents and persists 
out to 24 hours.85-87 Cipolla et al. show that the degree of autoregulatory failure assessed 
in MCAs extracted from rats undergoing MCAO is positively associated with the 
degree of actin cytoskeleton re-arrangement in the smooth muscle cells surrounding the 
isolated arteries.85 These observations may explain the persistent loss of autoregulation 
occurring despite reperfusion. mTOR inhibition with rapamycin has been shown to 
reduce cytoskeletal reorganisation and cell motility by supressing Rho-A expression in 
human rhabdomyosarcoma cell lines.88 Furthermore, rapamycin is currently used in 
drug eluting coronary stents to prevent smooth muscle hyperplasia by inhibiting mTOR 
mediated cytoskeletal re-arrangements and muscle cell proliferation.89 Rapamycin 
treatment has the potential to limit actin cytoskeletal re-arrangements in cerebral artery 
smooth muscle as a means of reducing autoregulatory failure and its harmful 
downstream effects on the BBB/NVU.  
Reducing the no-reflow phenomenon 
The no-reflow phenomenon was first described by Ames et al. in 1968.75 Since this 
initial report, a number of studies from different groups in different species have shown 
that the reduction in capillary perfusion post-recanalisation is associated with the 
aggregation of neutrophils, platelets and red blood cells within brain capillaries.78, 90-99 
Recent studies in rodents undergoing MCAO have shown that the degree of blood flow 
deficit on reperfusion is a stronger predictor of stroke outcome than intra-ischemic 
blood flow.76, 100 To date, the effect of rapamycin on post-recanalization perfusion 
deficits and cellular infiltration into capillaries after stroke has not been explored.  
Recent studies suggest that capillary obstruction in reflow may be caused by pericyte 
death in rigour.79, 80 This may contribute to cells such as red blood cells, neutrophils and 
platelets becoming trapped in capillaries as seen in previous studies. Pericyte 
constriction following ischemia has been shown to be caused by excessive calcium 
entry into the cytoplasm,79 which may lead to activation of the Rho 
GTPase/ROCK/myosin light chain (MLC) pathway resulting in rapid pericyte 
constriction.101, 102 As mentioned previously, mTOR inhibition with rapamycin has been 
shown to supress Rho-A expression.88 Therefore, rapamycin may lead to a reduction in 
phosphorylation of MLC, reducing the sensitivity of pericyte MLC to calcium and thus 
reduce the contractility of pericytes in response to excessive calcium influx during 
ischemia (Figure 2). The possibility of using rapamycin to reduce pericyte constriction 
and no-reflow phenomenon after stroke has not yet been directly investigated. 
Improving BBB Permeability 
The BBB is composed of brain endothelial cells and associated tight junctions.103 
Following ischemic stroke, BBB integrity becomes compromised leading to brain 
edema as a result of increased vascular permeability. Hyperglycaemia and diabetes 
further perturb BBB function, exacerbating edema.104, 105 Our understanding of BBB 
disruption after stroke is still evolving; however, recent evidence suggests that BBB 
compromise after stroke is mediated by a combination of ischemic damage to brain 
endothelial cells, endothelial cell cytoskeleton rearrangements, reactive astrogliosis and 
release of matrix metalloproteinases from pericytes (Figure 2), this will be discussed in 
more detail in the following paragraphs. 
Rapamycin can reduce endothelial cell death and improve junctional marker expression 
following ischemia in vitro. mTOR-dependent (rapamycin) and mTOR-independent 
(lithium carbonate) autophagy inducers were used in brain microvascular endothelial 
cells (BMVECs) in an oxygen and glucose deprivation (OGD) model and also an 
MCAO model, demonstrating a beneficial effect on BBB integrity (Figure 2).106 The 
potent autophagy inducer, long noncoding RNA MALAT1, has also been shown to 
protect brain endothelial cells from OGD.107 Furthermore, autophagy has been shown to 
be protective in advanced glycation end product induced early injury of human 
umbilical vein endothelial cells (HUVECs).108   
Rapamycin has been shown to decrease brain endothelial cell death and maintain the 
integrity of the BBB in in vivo models.32, 106, 109 In a rat focal model of cerebral 
ischemia, rapamycin reduced brain edema, infarct volume and improved behavioral 
outcomes.32 In a streptozotocin-induced model of diabetes, rapamycin decreased BBB 
permeability in control rats only following 1 hour of MCAO and two hours of 
reperfusion.110 The evidence for rapamycin improving BBB permeability is limited, 
however it does not appear to be as effective in diabetes, which may impact on efficacy 
in clinical scenarios.  
Energy failure within endothelial cells results in increased intracellular calcium, which 
can lead to MLC kinase activation and F-actin stress fibre formation, ultimately 
increasing paracellular permeability by changing endothelial cell shape and 
downregulating tight junctions between cells.111 Recently, the role of Rho kinase in 
BBB dysfunction has been explored. Rho kinase helps to determine vascular tone and 
integrity. Its effects include cell proliferation, inflammation, MLC phosphorylation and 
nitric oxide bioavailability. In an in vitro experiment using human brain microvascular 
endothelial cells (HBMECs) and astrocytes, the exacerbation of BBB damage in the 
context of hyperglycaemia was thought to be mediated by PKC-β through regulation of 
the RhoA/Rho kinase/MLC2 pathway.112 Similarly, another study using HBMECs and 
astrocytes demonstrated that increased RhoA/Rho kinase/MLC pathway activity in 
combination with changes in the actin cytoskeleton explain the endothelial barrier 
breakdown occurring following OGD (Figure 2).113 In an animal model of stroke, 
inhibition of Rho kinase modulated endothelial cell oxidative stress and tight junctions, 
improving the integrity of the BBB, which was supported in vitro using HBMECs and 
astrocytes.114 As mentioned in previous sections of this review, mTOR signalling is 
critical for activation of the Rho kinase pathway. Therefore, rapamycin treatment may 
not only improve BBB integrity by improving endothelial cell viability but also by 
direct stabilisation of the cytoskeleton and tight junctions.  
Astrocytes also play a critical role in maintaining the integrity and function of the BBB, 
as well as being key players in neuronal function through energy transfer, 
neurotransmitter recycling and antioxidant activity.115 In the first few hours after stroke, 
astrocytes take on a cytotropic phenotype, which is non-proliferative and favours 
neuronal survival. They mediate this by increasing glutamate uptake to reduce cytotoxic 
damage to neurons, they provide metabolic support to neurons and also provide 
antioxidant protection (Figure 2).116 As these astrocytes are non-proliferative, they 
maintain their endfoot process contacts with neurons and the vasculature. At around 6 
hours following ischemia, astrocytes begin to transition to a cytotoxic or reactive 
phenotype in which they reduce glutamate uptake,117 undergo cellular hypotrophy, up 
regulate the cytoskeletal protein glial fibrillary acid protein (GFAP),118 increase 
aquaporin 4 (AQP4) expression,118 increase matrix-metalloproteinase (MMP) release,119 
and retract their end foot processes from the vasculature,120 resulting in BBB disruption 
and impairment of neurovascular coupling (the regulation of blood flow in accordance 
with neuronal activity) (Figure 2). Therapies that can reduce the transition of astrocytes 
from cytotropic to cytotoxic reactive phenotype may aid in neuronal survival, reduce 
BBB disruption and improve post-stroke recovery.115 
Initial acute therapeutic efforts were directed at globally inhibiting the actions of 
astrocytes to improve outcome following stroke. This ultimately worsened injury, due to 
the pro-survival role of astrocytes in the acute phase.121, 122 mTOR has been shown to be 
a key mediator of the transition to reactive astrocytes during ischemia. Li et al.123 
showed that rapamycin treatment of astrocytes exposed to OGD reduced reactive gliosis 
as evidenced by reduced GFAP expression, reduced migration and reduced expression 
of pro-inflammatory cytokines (Figure 2). Inhibition of reactive gliosis may be another 
potential mechanism of reduced BBB permeability following rapamycin treatment.  
The effect of rapamycin on reactive astrogliosis, and how this relates BBB permeability 
in vivo, is just starting to be explored. In a rat model of transient MCAO and 
reperfusion, rapamycin decreased infarct volume and maintained the integrity of the 
BBB potentially via inhibiting the expression of matrix metalloproteinase 9 (MMP-9) 
and AQP4.124 AQP4 expression in the brain is astrocyte end-foot specific, however, the 
source of MMP-9 was not determined. Cultured astrocytes have been shown to enhance 
MMP-2 and MMP-9 expression and activity following in vitro ischemia.119 Recent 
evidence suggests that pericyte somata are a major source of MMP-9 in ischemia, which 
is associated with localised BBB disruption, primarily at pericyte locations along the 
capillary.125 Cultured pericytes have been shown to release MMP-9 but not MMP-2 by 
p38 MAPK dependent mechanisms.126 Furthermore, ischemia has been shown to induce 
p38 MAPK activation127 and rapamycin has previously been shown to reduce p38 
MAPK activation by inducing the expression of MAPK phosphatase activity.128 
Although this is a plausible mechanism for the reduced MMP-9 observed in the above 
studies, the effect of rapamycin on astrocyte or pericyte MMP release is yet to been 
investigated directly. Together, these studies suggest that whilst the integrity and 
function of the BBB in stroke is severely compromised, rapamycin has significant 
potential to alter many of the molecular mechanisms underlying these changes. 
Inflammation 
Regulation of an effective inflammatory response post-stroke is critical for a good 
outcome.129, 130 The immune system, largely comprised of microglia, is often described 
as ‘Janus faced’, with positive as well as negative effects in the CNS.131 There is a need 
for the phagocytotic clearance of dead tissue, and yet the paradoxical pro-inflammatory 
response this engenders results in the death of bystander cells by chemical ‘friendly 
fire’. In addition to the CNS immune system, invading leukocytes—largely neutrophils 
and monocytes—result in exacerbation of damage. The mechanisms for activation of 
both the local and systemic immune systems remain under scrutiny. 
CNS inflammation 
Microglial phagocytosis of apoptotic cells is a largely anti-inflammatory process,132 
resulting in the release of substances such as TGFβ. However, the exact mechanisms of 
cell death within the infarct core in stroke remain contentious. Release of factors such as 
HMGB during necrosis may induce a more pro-inflammatory phenotype in the local 
immune cell population.132 This double-edged sword has resulted in an increased 
interest in drugs with the capacity to polarise microglia. Whilst now considered much 
more of a spectrum, inducing an M1 or an M2 phenotype in the resident microglia 
remains an important goal.133 By reducing the pro-inflammatory effects of microglia 
potentially activated by necrotic cells, we may reduce the risk of both local damage, as 
well as the recruitment of peripheral immune cells. 
The literature surrounding mTOR pathway alterations, microglia and inflammation is 
contentious. For example, studies of glial cells in vitro have demonstrated that 
rapamycin prevents transition to an M2 phenotype, maintaining the M1 cytotoxicity and 
potentially enhancing microglial anti-tumour capacity.134 However, in a rodent model of 
stroke, mTOR pathway inhibition promoted an M2 phenotype, upregulating genes such 
as Arg1 and YM-1.135 The latter showed little significant difference between rapamycin 
and the more potent mTORC1 inhibitor, everolimus, suggesting this is a general 
pathway mechanism, rather than an Akt-specific effect. In a mouse permanent MCAO 
model, autophagy in microglia was shown to increase infarct size and edema, and was 
detrimental to neurological scores, with rapamycin promoting the inflammatory 
response.136 The discrepancy between these studies could be due to the in vitro vs. in 
vivo effects. Indeed, isolated cell culture experiments often report that rapamycin 
enhances the pro-inflammatory activity of microglia,137 whereas in whole animals this 
appears not to be the case. Xie and colleagues suggest this is likely to be due to cell-cell 
interactions after stroke. Their study demonstrated that the interaction between T-reg 
cells and macrophages/microglia in ischemia is an important regulator of inflammation, 
and that by enhancing the anti-inflammatory activities of T-regs, rapamycin indirectly 
reduces microglial pro-inflammatory abilities.138 
Systemic inflammation 
Whilst rapamycin is known to cross the BBB,139 systemic administration is likely to be 
used—should this drug become therapeutically viable in stroke—meaning that the 
immune effects of mTOR inhibition will be widespread. One of the first uses of 
rapamycin was as an immunosuppressant in transplant therapy, with rapamycin having 
broad effects on dendritic cells, 140 macrophages,141 monocytes,142 and T cells.143 This 
wide scale immunosuppressive activity may be beneficial in the post-stroke pro-
inflammatory environment, but given the importance of the inflammatory process in the 
repair process after stroke, this immunosuppression may be detrimental. 
The primary function of the mTOR pathway in post-stroke inflammation is via 
metabolic reprogramming to drive pro-inflammatory processes.144 For example, 
myeloid lineage cells are likely to need increased energy stores for replication and 
migration after an injury, but again, these processes may be affected by the polarisation 
of the cells.145 These changes in energy regulation are also likely to be context 
dependent. The nutrient-deficient environment in ischemia will prompt a metabolic shift 
in the cells and a polarisation towards a particular phenotype, potentially via mTORC1 
activation and metabolic reprogramming.146 Conversely, the nutrient- and oxygen-rich 
environment of the liver will result in systemic macrophages activated by damage-
associated proteins, which are likely to polarise to the opposing phenotype. When the 
latter migrate to the site of injury it is little wonder that there are conflicting findings in 
myeloid lineage experiments post-stroke.147, 148 Application of rapamycin to this system 
could prove problematic. Whilst low dose and short term rapamycin treatment has been 
shown to preferentially inhibit mTORC1, prolonged exposure or high doses are likely to 
inhibit mTORC2.149 As such, dosing regimens should be considered carefully. 
Migrating cells found within the CNS acutely post-stroke include significant numbers of 
neutrophils. Pro-inflammatory stimuli have been shown to exacerbate perfusion deficits 
following vessel recanalization, which are associated with increased platelet and 
neutrophil aggregation in capillaries.150 Specific to the no-reflow phenomenon, 
rapamycin has anti-neutrophil151, 152 and anti-platelet activity.153, 154 This may be, in part, 
due to mechanisms involving RhoA and the cytoskeletal changes required for 
chemotaxis. Knock down of this pathway in isolated neutrophils results in decreased 
chemotactic ability155 and therefore could be beneficial post-stroke. However, mTOR 
inhibition has also been shown to dysregulate the formation of neutrophil extracellular 
traps (NETs).156, 157 Dysregulation of NET formation may lead to complications such as 
sepsis,158 that would be highly undesirable in an already compromised patient. 
However, there is a paucity of data on the role of the mTOR pathway in neutrophils 
post-stroke. 
Further up the immunological tree lie the adaptive immune cells. Antigen-presenting 
dendritic cells, or even antigen-presenting microglia activate T cells post-stroke. 
Antigen presentation is a key process in adaptive immunity and is driven, in part, by 
autophagic pathways. There is a suggestion that basal autophagy is decreased in 
activated immune cells in order to prevent the excessive presentation of auto-antigens, 
and that interference with this pathway may increase this process. In fact, the treatment 
of transplant patients with rapamycin increases the levels of circulating autoreactive T 
cells, suggesting that the use of mTOR inhibitors in inflammatory cells may be 
dependent on activation status.159 When taken with data showing that rapamycin 
significantly impairs remyelination,160 there is a chance that poor dosing strategy may 
result in an autoreactive phenotype with poor remyelination, reminiscent of other major 
CNS diseases.  
Multi-target vs mono-target therapies  
Rapamycin may have a distinct advantage over previous and current neuroprotectants as 
it acts at a pivotal point governing a plethora of neurovascular protective effects (Figure 
2), rather than targeting a single pathway within the multi faceted ischaemic cascade. In 
this section we will discuss how the molecular targets of other neuroprotectants relate to 
those of rapamycin.  
As discussed previously, the main clinical use for rapamycin is in the context of 
immunosuppression following transplant161. This remains a potential mechanism by 
which rapamycin is neuroprotective following stroke.135, 162 The role of immune 
modulation is increasingly being investigated in stroke.163 Fingolimod, a T-cell 
modifying therapy used in multiple sclerosis, has been trialled in ischemic stroke 
patients in conjunction with alteplase.164 Neuroprotection is thought to be due to 
inhibiting the migration of lymphocytes, BBB stabilization,165 inhibiting the recruitment 
of leukocytes in cerebral microvessels and inhibition of endothelial activation.166 Small 
clinical trials have shown that fingolimod is well tolerated; however due to small patient 
numbers and heterogeneity of the trials, no definitive answer on the efficacy of this 
therapy can be made at this time.167  
Subcutaneous Interleukin-1 Receptor Antagonist (Anakinra) is another 
immunomodulatory therapy currently being trialled as an adjunct to thrombolysis in 
ischemic stroke.168 This intervention is backed up by many years of animal model 
evidence, systematic review and meta-analysis169 and a multicentre randomised pre-
clinical trial confirming its efficacy in improving stroke outcome.170 A recently 
published small phase-II randomised trial has confirmed that subcutaneous Anakinra is 
well tolerated, reduced circulating IL-6 levels but did not improve patient outcomes, 
potentially due to an interaction between Anakinra and alteplase. Larger studies are 
needed to investigate the efficacy of this therapy and the interaction with 
thrombolysis.168 
Rapamycin can protect the BBB leading to reduced brain edema after focal cerebral 
ischemia reperfusion in rodent models via multiple mechanisms including: reduced 
endothelial cell death via induction of autophagy,106 improved tight junction 
expression,106 inhibition of matrix metalloproteinase 9 (MMP9) and reduced aquaporin 
4 (AQP4) expression.171 Similarly the antibiotic minocycline has shown promising 
results in animal stroke models through reducing MMPs and hence the permeability of 
the BBB.172 However, the efficacy of improving stroke outcome in large human stroke 
trials has yet to be obtained.173  
Rapamycin can also reduce the detrimental effects of oxidative stress in neurons.174 This 
may be particularly important in the reperfusion phase when oxygen in re-introduced to 
defective or damaged mitochondria leading to reactive oxygen species production.175 
Rapamycin has been shown to be neuroprotective in an animal model of stroke by 
inducing mitophagy (removal of damage mitochondria by autophagy),176 which has 
been shown to reduce reactive oxygen species production and ultimately cell death.177 
Numerous anti-oxidants have been trialled for stroke. The most notable being NXY-
059, which showed promising results in numerous animal models and provided the 
impetus for two randomised trials, the first smaller SAINT-I trial showed a protective 
effect while the follow up larger SAINT-II trial was neutral for improving patient 
outcome.178 Post-hoc analysis of the animal studies that informed the decision to 
proceed to clinical trial showed that the poor quality of these studies may have led to an 
overestimation of the intervention’s efficacy.179 Furthermore, it has recently been shown 
that NXY-059 does not have biological efficacy in embryonic stem cell derived human 
neurons exposed to both ischemia and oxidative stress models of cell death.180 
Therefore, alternative anti-oxidant therapies that are based upon sound preclinical data 
and have been trialled in human neural tissue may still be a viable therapy for stroke.  
 
Translational considerations 
Overall rapamycin has the potential to suppress the deleterious effects of CNS immune 
activation on stroke outcome, however optimal dosing must be considered in order to 
keep detrimental systemic immunosuppression to a minimum. Different dosing 
strategies for rapamycin have been used in studies of the anti-ageing effects of 
rapamycin in rodents. These studies have shown that the beneficial anti-ageing effects 
of rapamycin are mediated through mTORC1 inhibition, while the detrimental side 
effects of long-term rapamycin administration such as immunosuppression and glucose 
intolerance are mediated by mTORC2 inhibition.182 Studies by Arriola Apelo et al. have 
shown that an alternative dosing strategy where rapamycin is administered once every 5 
days (as compared to once a day) inhibits mTORC1 without inhibiting mTORC2, 
increases longevity while reducing the negative effects on the immune system and 
glucose homeostasis.183, 184 Specifically, they found that a single 1mg/kg dose of 
rapamycin was enough to suppress mTORC1 activation for 1- 3 days post-
administration.183 This would be an ideal approach for treating stroke patients. A single 
low-dose administration within 6 hours post-stroke would be expected to provide the 
beneficial neuroprotective effects via mTORC1 inhibition for the initial phases of 
stroke. Rapamycin would then be cleared from the brain by 3 days, thus allowing the 
critical neural and angiogenic proliferation necessary for stroke recovery.185 
One must also consider the route of administration. Rapamycin is a large hydrophobic 
macrocyclic lactone (Figure 3A), which makes it advantageous for crossing cell 
membranes and the BBB. However, this makes it difficult to get into solution for ease 
of intravenous administration. Therefore, rapamycin has traditionally been given by 
mouth in tablet or liquid formulation (with ethanol to improve solubility).186 This may 
be problematic for acute administration to stroke patients given that 65% of these 
patients have difficulty swallowing and protecting their airways.187 To allow acute 
administration of rapamycin to these patients, a naso-gastric tube would allow safe 
administration of a rapamycin solution. This may pose some problems in terms of time 
needed to place the tube, the added time needed for the drug to reach the bloodstream 
and the drug being subject to extensive first-pass metabolism by CYP3A enzymes in the 
intestine and the liver.188 If rapamycin is to persist as a potential therapy, these routes of 
administration should also be considered in pre-clinical research. 
An alternate strategy would be to give the rapalogue temsirolimus, which comes as an 
intravenous formulation.186 Temsirolimus is the pro-drug of sirolimus that once 
administered intravenously is rapidly converted to sirolimus (Figure 3B).189 
Temsirolimus is currently approved for the treatment of renal cell carcinoma.190 
Although temsirolimus is a pro-drug of sirolimus this analogue appears to have very 
similar potency and tolerability when compared to sirolimus.191 Therefore, it is 
anticipated that temsirolimus would exert the same neuroprotective effects in stroke as 
regular sirolimus. However, this has yet to be tested experimentally.  
 
 
Conclusion 
Neurons do not work in isolation. It is increasingly recognized that cerebrovascular and 
immunological factors influence neuronal survival following stroke. Investigations into 
drugs that target certain hubs of the complex cell death cascade are on going. 
Rapamycin not only targets multiple facets of this complex biological cascade, but it 
also has immunological properties and effects on blood flow. Coupled with the fact that 
rapamycin already has known biological efficacy and dose tolerability in human 
patients for transplant and cardiovascular medicine, means that it may rapidly and 
relatively cheaply be repurposed for use as an adjunct stroke therapy to the gold 
standards of thrombolysis and thrombectomy - protecting neurons until perfusion could 
be restored.181 
Exploring the role of mTOR in neurovascular and neuroimmune regulation is in its 
infancy. An increased understanding of how this pathway contributes to pathology will 
be key for developing novel therapies. Further investigations are needed into the precise 
molecular mechanisms of rapamycin, the most efficacious dosing, and optimal timing in 
relation to ischemic stroke. By targeting multiple processes within the neurovascular 
unit post-stroke we may extend the time window for effective restoration of blood flow 
and improve functional outcomes in stroke patients.  
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Figure Legends  
Figure 1. The role of mTOR in neuronal survival following ischemia. A. Under 
normal conditions the adequate provision of nutrients and oxygen activates mTOR to 
stimulate anabolic processes such as protein synthesis while suppressing catabolic 
processes such as autophagy. B. During stroke the reduction in provision of nutrients 
reduces mTOR activation, limiting protein synthesis and inducing autophagy. C. 
Treatment of neurons with rapamycin can further reduce mTOR activation and increase 
the induction of autophagy. If autophagy induction is optimal this may lead to cell 
component recycling and cell survival (right-hand box). If autophagy is excessive, this 
may lead to apoptosis and cell death (left-hand box). mTORC1, mammalian target of 
rapamycin complex 1; S6K, S6kinase; S6rp, S6 ribosomal protein; 4EBP, eukaryotic 
translation initiation factor 4E binding protein; eIF4e, eukaryotic  initiation factor 4e.  
Figure 2: Suggested neurovascular effects of rapamycin. Astrocyte: Stroke/hypoxia 
causes conversion of astrocytes from cytotropic to cytotoxic driven by mTOR and 
retraction of astrocytes from the BBB driven by Rho-GTP. Rapamycin treatment stops 
transition from cytotropic to cytotoxic phenotype in cell culture. Rapamycin can 
potentially reduce the retraction of astrocytic endfeet and improve BBB permeability by 
inhibiting RhoA-GTP (Hypothetical). Pericyte: Stroke/hypoxia causes pericyte 
constriction and MMP-9 release (animal and cell culture). Rapamycin may reduce 
constriction by RhoA-GTP (hypothetical). Rapamycin can reduce MMP-9 expression 
following stroke (shown in animal models). Endothelial cells: Stroke/hypoxia can 
cause reduced CBF, endothelial cell death and tight junction breakdown. Excess 
calcium entry into the endothelial cell leads to cytoskeletal re-arrangements by myosin 
light chain phosporylation and stress fibre formation leading to BBB opening. 
Rapamycin can increase eNOS activity and improves CBF in AD mouse models. 
Rapamycin increases autophagy leading to enhanced cell viability and tight junction 
expression (based on cell culture and animal studies). Rapamycin can reduce Rho-A 
mediated cytoskeletal rearrangements by inhibiting mTOR s6K (hypothetical). 
 
Figure 3. Rapamycin (Sirolimus) and Rapalogues A. Chemical structure of 
Sirlolimus. B. Chemical Structure of Temsirolimus. Substitution of the C40 hydroxyl 
group is shown in blue.192  
 
